Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from MacroGenics ( (MGNX) ) is now available.
On November 14, 2025, MacroGenics announced the departure of Dr. Stephen Eck, its Senior Vice President, Clinical Development and Chief Medical Officer, effective December 31, 2025. Dr. Eck, who joined the company in July 2020, led its clinical development efforts across multiple studies. In his absence, Frank Perabo will assume interim oversight of clinical development, while the company searches for a new Chief Medical Officer. This leadership change may impact MacroGenics’ clinical development operations and strategic direction.
The most recent analyst rating on (MGNX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.
Spark’s Take on MGNX Stock
According to Spark, TipRanks’ AI Analyst, MGNX is a Neutral.
MacroGenics’ overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing profitability issues and cash flow management difficulties. The technical analysis indicates a bearish trend, and the valuation metrics highlight significant concerns with a negative P/E ratio. These factors collectively contribute to a lower stock score.
To see Spark’s full report on MGNX stock, click here.
More about MacroGenics
MacroGenics, Inc. operates in the biotechnology industry, focusing on the development of innovative antibody-based therapeutics for the treatment of cancer.
Average Trading Volume: 872,569
Technical Sentiment Signal: Strong Sell
Current Market Cap: $89.83M
Find detailed analytics on MGNX stock on TipRanks’ Stock Analysis page.